CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL101) in B-cell Receptor Pathway Inhibition in CLL
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Idelalisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- Acronyms CALiBRe
- 31 May 2017 Status changed from active, no longer recruiting to completed.
- 29 Mar 2016 Accrual to date is 52% according to United Kingdom Clinical Research Network record.
- 03 Nov 2015 Accrual to date according to UK Clinical Research Network is 22%.